Cantor Fitzgerald analyst Eliana Merle reiterated a Buy rating on CymaBay Therapeutics (CBAY) yesterday and set a price target of $20. The company’s shares closed yesterday at $9.
“. We reiterate our Overweight and $20 PT. We think that there is limited read-through clinically from GILD’s (OW, A. Young) STELLAR4 selonsertib failure to CBAY’s seladepar mechanism of action. We also think that GILD remains committed to NASH/liver disease, so we think that the company could acquire assets where it does not currently have mechanisms of action like PPAR- delta. We see no read-through from ASK1 setback to PPAR-delta agonist seladepar.”
According to TipRanks.com, Merle is a 1-star analyst with an average return of -5.9% and a 25.0% success rate. Merle covers the Healthcare sector, focusing on stocks such as Aerpio Pharmaceuticals Inc, AnaptysBio Inc, and Galapagos NV.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CymaBay Therapeutics with a $17.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.59 and a one-year low of $6.31. Currently, CymaBay Therapeutics has an average volume of 626.5K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Carl Goldfischer, a Director at CBAY sold 11,675 shares for a total of $105,309.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of biopharmaceutical products. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid.